A novel nomogram for predicting hyperprogressive disease after immune checkpoint inhibitor treatment in lung cancer

被引：1
|
作者：
Cao, S. [1 ]
Zhong, H. [2 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm Med, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Pulm Med Dept, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.02.082
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
73P
引用
收藏
页码：S64 / S64
页数：1
相关论文
共 50 条
  • [21] Hyperprogressive Disease After Treatment With Checkpoint Inhibitors Time for Prospective Studies
    Santana-Davila, Rafael
    JAMA ONCOLOGY, 2020, 6 (07) : 1046 - 1047
  • [22] Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
    Shen, Pan
    Han, Liang
    Ba, Xin
    Qin, Kai
    Tu, Shenghao
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [23] Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma
    M. Schuiveling
    E. H. J. Tonk
    R. J. Verheijden
    K. P. M. Suijkerbuijk
    Cancer Immunology, Immunotherapy, 2021, 70 : 1491 - 1496
  • [24] Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
    Ayala de Miguel, P.
    Lopez Gallego, J.
    Gorospe Garcia, I.
    Illan Varella, A.
    Rivera Vargas, P. R.
    Posada Restrepo, A.
    Borrega Garcia, P.
    ANNALS OF ONCOLOGY, 2019, 30
  • [25] Hyperprogressive Disease in Advanced Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
    Lo Russo, G.
    Signorelli, D.
    Proto, C.
    Galli, G.
    Prelaj, A.
    Ferrara, R.
    Sommariva, M.
    Moro, M.
    Cancila, V.
    Ganzinelli, M.
    Brich, S.
    Sangaletti, S.
    Pruneri, G.
    Tripodo, C.
    Colombo, M. P.
    Rivoltini, L.
    Balsari, A.
    Sozzi, G.
    Boeri, M.
    Garassino, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S245 - S245
  • [26] Prediction model for hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitors
    Choi, Yong Jun
    Kim, Taehee
    Kim, Eun Young
    Lee, Sang Hoon
    Kwon, Do Sun
    Chang, Yoon Soo
    THORACIC CANCER, 2020, 11 (10) : 2793 - 2803
  • [27] Hyperprogressive disease in patients receiving immune checkpoint inhibitors
    Zhang, Haochen
    Fang, Xuefeng
    Li, Dan
    Yang, Mengyuan
    Yu, Linzhen
    Ding, Yuwei
    Shen, Hong
    Yuan, Ying
    CURRENT PROBLEMS IN CANCER, 2021, 45 (03)
  • [28] Hyperprogressive disease after immune checkpoint inhibitor therapy in a patient with non-small cell lung cancer who harbors a TGFBR2 mutation: A case report
    Wang, Xiaofang
    Mi, Xiao
    Li, Teng
    Li, Chengcheng
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2023, 25 (05)
  • [29] Development and validation of a nomogram for predicting the occurrence of renal dysfunction after treatment of immune checkpoint inhibitor: a retrospective case-control study
    Su, Jianan
    Chen, Pengwei
    Yang, Yaping
    Gao, Ziqing
    Bi, Zhuofei
    Feng, Min
    BMJ OPEN, 2024, 14 (05):
  • [30] Eosinophilic reactive airways disease after immune checkpoint inhibitor treatment
    Cordial, Parker
    Bentley, Ian D.
    Horowitz, Jeffrey C.
    Ho, Kevin
    RESPIROLOGY CASE REPORTS, 2024, 12 (09):
12345